Figure 1.

Frequency of irAEs for ICI monotherapy^a by (A) organ system (range) and (B) class of ICI and grade^b (median and range). Circles and lines represent the range of frequency. White circles in (A) represent <1%. Solid bars in (B) represent the median frequency. ^aMonotherapies include nivolumab, pembrolizumab, and ipilimumab. ^birAE grading according to National Cancer Institute Common Terminology Criteria for Adverse Events. (A) Data collated from prospective and retrospective phase 2 and 3 clinical studies summarized and cited in the study by Pardoll et al, Buchbinder et al, Tarhini et al, Haanen et al, and Puzanov et al.^9–11,13,14 The number of patients in clinical studies ranged from 14 to 1685. (B) Adapted from Michot et al, where the phase 2 and 3 clinical studies from which the data were summarized are cited.¹² The number of patients in these studies ranged from 135 to 799. CTLA-4, cytotoxic T lymphocyte antigen-4; DRESS, drug rash with eosinophilia and systemic symptoms; GI, gastrointestinal; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; PD-1, programmed death-1; PD-L1, programmed death-ligand 1.